IRMD icon

iRadimed

71.08 USD
-0.19
0.27%
At close Updated Sep 15, 10:19 AM EDT
1 day
-0.27%
5 days
-1.4%
1 month
0.99%
3 months
21.46%
6 months
36.43%
Year to date
29.38%
1 year
44.88%
5 years
227.26%
10 years
190.24%
 

About: iRadimed Corp develops, manufactures, markets and distributes a Magnetic Resonance Imaging (MRI) compatible intravenous (IV) infusion pump system, and MRI compatible patient vital signs monitoring system, and accessories and services relating to them. The company provides a non-magnetic IV infusion pump system which is designed to be safe for use during MRI procedures. The MRI products of the company are sold to hospitals and acute care facilities in the United States and internationally. It generates majority revenue from United States.

Employees: 160

0
Funds holding %
of 7,463 funds
Analysts bullish %

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

17% more repeat investments, than reductions

Existing positions increased: 62 | Existing positions reduced: 53

15% more capital invested

Capital invested by funds: $365M [Q1] → $421M (+$55.8M) [Q2]

0.67% more ownership

Funds ownership: 54.73% [Q1] → 55.4% (+0.67%) [Q2]

0% more funds holding in top 10

Funds holding in top 10: 1 [Q1] → 1 (+0) [Q2]

5% less funds holding

Funds holding: 168 [Q1] → 159 (-9) [Q2]

40% less first-time investments, than exits

New positions opened: 12 | Existing positions closed: 20

86% less call options, than puts

Call options by funds: $36K | Put options by funds: $251K

Financial journalist opinion

Neutral
GlobeNewsWire
19 days ago
IRADIMED CORPORATION to Participate in the 2025 Wells Fargo Healthcare Conference
ORLANDO, Fla., Aug. 26, 2025 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (NASDAQ: IRMD), a leader in innovative medical devices for Magnetic Resonance Imaging (“MRI”) compatible patient monitoring and infusion systems, today announced that it will participate in the Wells Fargo 2025 Healthcare Conference, held September 3-5, 2025, in Boston, Massachusetts.
IRADIMED CORPORATION to Participate in the 2025 Wells Fargo Healthcare Conference
Positive
Seeking Alpha
24 days ago
IRadimed: Continued Value Unlock With Extensive Reinvestment Runway
IRadimed Corporation demonstrates exceptional economic characteristics, with high NOPAT margins, robust free cash flow, and consistent value creation for shareholders. Management has effectively reinvested capital, generating over $18 in market value for every $1 invested since FY'22, and consistently exceeding a 12% ROIC hurdle rate. Despite modest sales growth, IRMD's profitability and cash conversion remain strong, with a persistent ability to redeploy earnings at attractive returns.
IRadimed: Continued Value Unlock With Extensive Reinvestment Runway
Positive
Zacks Investment Research
1 month ago
Recent Price Trend in iRadimed (IRMD) is Your Friend, Here's Why
iRadimed (IRMD) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
Recent Price Trend in iRadimed (IRMD) is Your Friend, Here's Why
Positive
The Motley Fool
1 month ago
Iradimed (IRMD) Q2 Revenue Jumps 14%
Iradimed (IRMD) Q2 Revenue Jumps 14%
Iradimed (IRMD) Q2 Revenue Jumps 14%
Neutral
Seeking Alpha
1 month ago
IRADIMED CORPORATION (IRMD) Q2 2025 Earnings Call Transcript
IRADIMED CORPORATION (NASDAQ:IRMD ) Q2 2025 Earnings Conference Call August 1, 2025 11:00 AM ET Company Participants John F. Glenn - CFO & Corporate Secretary Roger E.
IRADIMED CORPORATION (IRMD) Q2 2025 Earnings Call Transcript
Positive
Zacks Investment Research
1 month ago
iRadimed (IRMD) Q2 Earnings and Revenues Surpass Estimates
iRadimed (IRMD) came out with quarterly earnings of $0.49 per share, beating the Zacks Consensus Estimate of $0.45 per share. This compares to earnings of $0.42 per share a year ago.
iRadimed (IRMD) Q2 Earnings and Revenues Surpass Estimates
Neutral
GlobeNewsWire
1 month ago
IRADIMED CORPORATION Reports Record Second Quarter 2025 Financial Results
Announces Regular Quarterly Cash Dividend of $0.17 Per Share Raises Full Year 2025 Revenue and Earnings Guidance Reports record revenue of $20.4 million for the second quarter of 2025, an increase of $2.5 million, or 14%, compared to the same period in 2024. Reports record GAAP diluted EPS of $0.45 and non-GAAP diluted EPS of $0.49 for the second quarter of 2025, which are increases of 18% and 17%, respectively, compared to the same period in 2024.
IRADIMED CORPORATION Reports Record Second Quarter 2025 Financial Results
Neutral
GlobeNewsWire
1 month ago
IRADIMED CORPORATION to Hold Second Quarter of 2025 Financial Results Conference Call on August 1, 2025
ORLANDO, Fla., July 25, 2025 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (NASDAQ: IRMD) announced today that the Company will release its 2025 second quarter financial results before the market opens on Friday, August 1, 2025. Iradimed management will host a conference call the same day beginning at 11:00 a.m. Eastern Time to discuss those results and to answer questions.
IRADIMED CORPORATION to Hold Second Quarter of 2025 Financial Results Conference Call on August 1, 2025
Negative
Zacks Investment Research
3 months ago
New Strong Sell Stocks for June 12th
LYB, IRMD and SONY have been added to the Zacks Rank #5 (Strong Sell) List on June 12, 2025.
New Strong Sell Stocks for June 12th
Neutral
GlobeNewsWire
3 months ago
IRADIMED CORPORATION Announces FDA 510(k) Clearance for MRidium® 3870 Infusion Pump System
WINTER SPRINGS, Fla., May 29, 2025 (GLOBE NEWSWIRE) -- Iradimed Corporation (NASDAQ: IRMD), a global leader in innovative medical devices for MRI environments, today announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for its next-generation MRidium® 3870 IV Infusion Pump System. This advanced, MRI-compatible infusion pump extends Iradimed's unique position as the world's only supplier of non-magnetic MRI infusion pump devices, established with our first-generation device in 2005.
IRADIMED CORPORATION Announces FDA 510(k) Clearance for MRidium® 3870 Infusion Pump System
Charts implemented using Lightweight Charts™